I am currently the Chief Legal Officer of Cargo Therapeutics, a public biotechnology company focused on developing next-generation CAR T therapies. In addition, I serve on 3 public company boards, chair 2 Nominating & Governance Committees, and serve on 3 Audit Committees. Previously, I was the Chief Operating Officer of Adagio Therapeutics (now known as Invivyd) and was its first full-time employee. Invivyd is focused on developing broadly neutralizing antibodies for the prevention and treatment of Covid-19 and future coronavirus outbreaks. In under 14 months, we went from day 1 to IPO, raising over $700M over a series of financing rounds, moved our lead antibody into Phase 2/3 clinical trials, hired 70+ team members, and prepared the company for a seamless transition to public company status. Prior to Adagio/Invivyd, I led Ironwood’s corporate development function which was responsible for a full range of corporate transactions, including M&A, licensing and collaborations. I also managed Ironwood’s legal, compliance and commercial regulatory functions. I joined Ironwood in 2008 and helped lead the organization through dramatic growth and transformation, including its evolution from a privately-held, research-based organization to a publicly-traded, fully-integrated and very successful commercial biotechnology company. I have two decades of experience navigating biopharmaceutical companies through similar transformational changes, as well as expertise in corporate transactions, governance, and the operational issues relevant to launching new medicines into specialty and primary care markets.I started my career as an M&A associate with Skadden Arps, and have loved managing complex transactions ever since.